BioByte 106: B cell depletion therapies branching out, glycoRNAs for targeted therapeutic delivery, breaking from tradition in scientific publishing and optimizing data for AI-enabled drug discovery

BioByte 105: sequencing by expansion, self-driving labs for novel lipid discovery, mass spec proteomics, and a return to Asilomar

BioByte 104: the release of Evo 2, validating free-form hypotheses at scale, shedding light on astrocytes, and a guide to biotech partnerships

BioByte 103: drug discovery's DeepSeek moment, microfluidics and deep learning for mapping proteins, a novel means of metabolite detection, and evaluating Deep Research with a tox task

BioByte 102: AI reasoning models for science, pharma deals for TechBio, R-loops in psychiatric indications, & the launch of a long-awaited non-opioid painkiller

JPM-Byte 2025

Scaling Biology 003: Sam Rodriques, Co-Founder and CEO at FutureHouse

BioByte 101: de novo antibody design, measuring how fast your brain is aging, enhancing GWAS, commentary on trial results, and more

BioByte 100: integrating biological complexity into AI, scaling connectomics to the human brain, deep brain stimulation for spinal cord injury, ESM Cambrian launch

BioByte 099: Ferroptosis across disease, adipose retains epigenetic memory, Cephalopod-inspired drug delivery, and predicting RNA 3D structures

BioByte 098: big challenges in protein-design, OpenAI takes clinical trials, how non-neural cells remember and predicting psychiatric disease from social media.

BioByte 097: Drivers of biological progress, immunogenicity in gene therapy & a vision for AI scientists